David Moatazedi
هذا المحتوى غير متوفر بلغتك بعد.
David Moatazedi is the Chief Executive Officer of Evolus. His relevance to the botulinum toxin industry comes from Evolus’s role in Jeuveau commercialization and the company’s self-pay aesthetics strategy.
Moatazedi’s role helps separate commercial leadership from manufacturing identity. Daewoong Pharmaceutical is the product-origin and manufacturing company for the Nabota / Jeuveau family, while Evolus is the U.S. commercial company for Jeuveau and uses Nuceiva in selected markets outside the United States.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Evolus |
| Current role | Chief Executive Officer |
| Industry relevance | Evolus commercial leadership for Jeuveau / Nuceiva market structure |
| Relevant companies | Evolus and Daewoong Pharmaceutical |
| Relevant brand | Jeuveau / Nabota |
| Market context | Self-pay aesthetics rather than a broad therapeutic toxin franchise |
Career Notes
Section titled “Career Notes”- Evolus investor materials describe the company as focused on the cash-pay aesthetic market.
- Evolus presents Jeuveau as its U.S. neurotoxin brand and Nuceiva as the name used outside the United States.
- SEC and investor-relations materials identify Evolus as a Nasdaq-listed company, making Moatazedi useful for public-company leadership context.
- Jeuveau’s U.S. label identifies the product as prabotulinumtoxinA-xvfs and preserves product-specific unit and indication limits.
Jeuveau Commercialization Context
Section titled “Jeuveau Commercialization Context”Moatazedi matters because Jeuveau is a clear example of split roles in the toxin market. Daewoong developed and manufactures the product family, while Evolus handles important aesthetic commercialization rights. Readers asking who “makes” Jeuveau often need both answers separated: manufacturing origin is Daewoong; U.S. commercial identity is Evolus.
That split does not make Nabota, Jeuveau, and Nuceiva one universal regulatory label. It also does not imply that Jeuveau units can be converted into units of Botox, Dysport, Xeomin, Daxxify, Letybo, or another product.
Activity and Public Context
Section titled “Activity and Public Context”Moatazedi’s Evolus and Jeuveau / Nabota relevance is public-company leadership and commercialization structure. Clinical claims should remain anchored to Jeuveau prescribing information and local product approvals.